All Stories

  1. Neuropsychological recovery during the first 12 months after severe traumatic brain injury: A longitudinal study with monthly assessments
  2. Single-Case Experimental Designs
  3. Research Note: Single-case experimental designs
  4. Personalised treatments for acute whiplash injuries: A pilot study of nested N-of-1 trials in a multiple baseline single-case experimental design
  5. An Algorithm to Evaluate Methodological Rigor and Risk of Bias in Single-Case Studies
  6. Integrating routine clinical interventions with single-case methodology: Parallels, differences and bridging strategies
  7. Normes de présentation de recherche utilisant les protocoles à cas unique en interventions comportementales (SCRIBE-2016)
  8. Reprint of “The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016: Explanation and Elaboration”
  9. Introduction to single-case experimental designs
  10. Maximising validity in single-case designs
  11. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings
  12. Multiple-baseline designs
  13. Alternating-treatments designs
  14. Withdrawal/reversal designs
  15. Changing-criterion designs
  16. Practical application of single-case methods in the neurorehabilitation setting
  17. Data evaluation
  18. The independent variable
  19. The dependent variable
  20. Quantitative Data Analysis for Single-Case Methods, Between-Groups Designs, and Instrument Development
  21. Introduction to the Special Issue on Rare and Unusual Syndromes
  22. Null Hypothesis Significance Testing,p-values, Effects Sizes and Confidence Intervals
  23. Reversible cerebral vasoconstriction syndrome
  24. Reporting Single-Case Research in The Neurorehabilitation Literature: A Systematic Review Indicates There is Room for Improvement
  25. The Alice in Worderland Syndrome
  26. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement†
  27. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  28. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  29. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  30. The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) 2016 statement
  31. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 statement
  32. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  33. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  34. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 statement.
  35. Supplemental Material for The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016: Explanation and Elaboration
  36. Supplemental Material for The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  37. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
  38. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016: Explanation and elaboration.
  39. N-of-1 Trials in the Behavioral Sciences
  40. Some Thoughts about the Suitability of the Reliable Change Index (RCI) for Analysis of Ordinal Scale Data
  41. Single-Case Experimental Designs
  42. Single-case experimental designs: Reflections on conduct and analysis
  43. Single case experimental designs: Introduction to a special issue ofNeuropsychological Rehabilitation
  44. The design, conduct and report of single-case research: Resources to improve the quality of the neurorehabilitation literature
  45. Revision of a method quality rating scale for single-case experimental designs andn-of-1 trials: The 15-item Risk of Bias inN-of-1 Trials (RoBiNT) Scale
  46. Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use
  47. Corrigendum
  48. Single-subject designs as a tool for evidence-based clinical practice: Are they unrecognised and undervalued?
  49. The methodological quality of aphasia therapy research: An investigation of group studies using the PsycBITETMevidence‐based practice database
  50. Applying the International Classification of Functioning, Disability and Health (ICF) to Clinical Practice and Research in Acquired Brain Impairment
  51. Rating the methodological quality of single-subject designs andn-of-1 trials: Introducing the Single-Case Experimental Design (SCED) Scale
  52. The neuropsychological correlates of cannabis use in schizophrenia: Lifetime abuse/dependence, frequency of use, and recency of use
  53. The Neuropsychology of Cannabis and other Substance use in Schizophrenia: Review of the Literature and Critical Evaluation of Methodological Issues
  54. The Evidence Base of Neuropsychological Rehabilitation in Acquired Brain Impairment (ABI): How Good is the Research?
  55. Improving evidence‐based practice in rehabilitation: Introducing PsycBITETM
  56. Update on Cicerone’s Systematic Review of Cognitive Rehabilitation: The PsycBITE Perspective
  57. How Do You Know Whether Your Patient Is Getting Better (or Worse)? A User's Guide
  58. Development of a database of rehabilitation therapies for the psychological consequences of acquired brain impairment
  59. Predicting Duration of Posttraumatic Amnesia (PTA) from Early PTA Measurements
  60. Measuring Psychological Adjustment to HIV Infection
  61. Posttraumatic stress disorder in response to HIV infection
  62. Suicidal Ideation, Suicide Attempts, and HIV Infection
  63. Stability of the Wisconsin Card Sorting Test and the Determination of Reliability of Change in Scores
  64. Psychiatric Disorder in HIV Infection
  65. HIV
  66. Clinical Markers of the Presence of Dementia and Neuropsychological Impairment in HIV Infection
  67. Neuropsychological function in asymptomatic HIV-1 infection: Methodological issues
  68. Anxiety, Depression and HIV Related Symptomatology across the Spectrum of HIV Disease
  69. Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS
  70. HIV Nomenclature
  71. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection
  72. Fifth International Conference on the acquired immunodeficiency syndrome
  73. Hochauflösende Augenmotilitätsmessungen bei der Untersuchung neurologischer Komplikationen der HIV-1-Infektion
  74. THE NEUROLOGICAL FEATURES OF EARLY AND ‘LATENT’ HUMAN IMMUNODEFICIENCY VIRUS INFECTION
  75. Simple and choice reaction time in patients with human immunodeficiency virus infection
  76. The prevalence of the Wernicke-Korsakoff syndrome in Sydney, Australia: a prospective necropsy study.
  77. Fourth International Conference on the acquired immunodeficiency syndrome
  78. The Wernicke‐Korsakoff syndrome in Sydney — a prospective necropsy study
  79. Eye Movement Abnormalities as a Predictor of the Acquired Immunodeficiency Syndrome Dementia Complex
  80. Characterization of the Acute Clinical Illness Associated With Human Immunodeficiency Virus Infection